Abstract: Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. To our knowledge, this is the first described case of toxic epidermal necrolysis due to fulvestrant. A 56-year-old woman received 500 mg of intramuscular fulvestrant monthly for metastatic ductal carcinoma of the breast. Five days after the first dose, the patient presented with a maculopapular rash that evolved to blisters, and a detachment of the epidermis in over 30% of the total body surface area. Histological analysis was compatible with toxic epidermal necrolysis. Fulvestrant was discontinued, topical management and supportive care were initiated.
INTRODUCTION
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare conditions characterized by apoptosis, as well as detachment of the epidermis and mucous membranes. 1 It results from type IV hypersensitivity reactions. 2 In these cases, there is elevation of the Fas ligand, which binds to Fas (its receptor of keratinocytes) and induces massive keratinocyte apoptosis. 1 SJS and TEN are frequently drug related. The most commonly responsible agents are sulfonamides, allopurinol, antiepileptic, and non-steroidal anti-inflammatory drugs (Chart 1). 3 SJS and TEN are currently regarded as different degrees of the same disease spectrum. These conditions differ by the extent of epidermal detachment; while TEN involves more than 30% of the total body surface area, SJS involves less than 10%. 1 A high diagnostic suspicion for TEN is important, as the associated mortality rates can be as high as 25-35%. Withdrawal of the responsible drug is crucial in the prognosis. To our knowledge, this report presents the first described case of TEN due to fulvestrant.
CASE REPORT
A 56-year-old female with a history of ductal carcinoma of the breast underwent a mastectomy and ipsilateral axillary lymph node resection, and she also received a chemotherapy regimen of docetaxel, adriamycin, and cyclophosphamide. The patient underwent radiotherapy and hormone therapy with tamoxifen 6 years ago. Two years ago, she relapsed and presented with lung and bone metastases. She was then treated with capecitabine. Recently, she presented with deviation of the oral commissure and was diagnosed with brain metastasis. Given the lack of response to treatment, and Skin care is based on minimizing trauma, puncturing blisters, and using antiseptics and non-adherent mesh gauze for ero- The use of steroids in the treatment of TEN is based on case reports and case series. An increased rate of infections, a delay of re-epithelialization, and prolonged hospitalization has been reported with the use of steroids. 8 Steroids have not been shown to have any effect on mortality rates. 9 Valeyrie-Allanore performed a clinical trial to evaluate the possible benefits and safety profile of cyclosporine in patients with SJS/TEN. They concluded that cyclosporine decreased expected death rate according to SCORTEN. 10 Given the presence of the underlying disease and the lack of a firm evidence-based recommendation for the use of systemic therapy for the treatment of TEN, the patient was exclusively managed with topical treatment and supportive care with a favorable outcome. It should be noted that the skin reactions induced by fulvestrant are rare. Regarding systemic treatment, corticosteroids and intravenous immunoglobulins (IVIG) are the most commonly used drugs.
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The use of IVIG is extended by the discovery that IVIG blocks the
